Biomarker & Intervention Discovery
Ovarian Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs335.5KWHO GHE 2021 · all ages
Global DALYs5.82MWHO GHE 2021 · worldwide
US mortality13.5K deaths/yrWHO GHE 2021
Global mortality191.0K deaths/yrWHO GHE 2021 · worldwide
NIH funding$177MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionNo spontaneous remission; 5-year survival Stage I: 90%; Stage III/IV: 25-30%; most patients (75%) present at Stage…
Best-intervention remissionDebulking surgery + carboplatin/paclitaxel: 70-80% initial response; PARP inhibitors (olaparib, rucaparib) maintenance…
Gap sizeLarge — PARP inhibitors dramatically improve outcomes in BRCA-mutant patients; HRD testing not universal; no effective…
Primary barrieraccess + biological
Full remission profile →
Remission & chronicity
Spontaneous remission
No spontaneous remission; 5-year survival Stage I: 90%; Stage III/IV: 25-30%; most patients (75%) present at Stage III-IV
Best-intervention remission
Debulking surgery + carboplatin/paclitaxel: 70-80% initial response; PARP inhibitors (olaparib, rucaparib) maintenance in BRCA-mutant: 56% 5-year PFS vs 13.8% placebo (SOLO-1); bevacizumab maintenance: modest PFS benefit; dose-dense paclitaxel: 72.1% vs 65.1% OS at 3 years
Gap size
Large — PARP inhibitors dramatically improve outcomes in BRCA-mutant patients; HRD testing not universal; no effective screening exists
Primary barrier
access + biological
BRCA1/2 and HRD testing is not universal despite major impact on PARP inhibitor eligibility; bevacizumab access limited by cost; most patients are diagnosed at advanced stage due to no screening modality; CA-125 + transvaginal ultrasound screening trials (UKCTOCS) failed to show mortality reduction
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Ovarian Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."